GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Net Margin %

ISCO (International Stem Cell) Net Margin % : -12.02% (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. International Stem Cell's Net Income for the three months ended in Mar. 2025 was $-0.26 Mil. International Stem Cell's Revenue for the three months ended in Mar. 2025 was $2.13 Mil. Therefore, International Stem Cell's net margin for the quarter that ended in Mar. 2025 was -12.02%.

The historical rank and industry rank for International Stem Cell's Net Margin % or its related term are showing as below:

ISCO' s Net Margin % Range Over the Past 10 Years
Min: -81.4   Med: -17.14   Max: -1.68
Current: -2.76


ISCO's Net Margin % is ranked better than
70.38% of 979 companies
in the Biotechnology industry
Industry Median: -107.79 vs ISCO: -2.76

International Stem Cell Net Margin % Historical Data

The historical data trend for International Stem Cell's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Net Margin % Chart

International Stem Cell Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.22 -12.53 -4.05 -1.68 -2.30

International Stem Cell Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.05 5.11 -5.74 0.45 -12.02

Competitive Comparison of International Stem Cell's Net Margin %

For the Biotechnology subindustry, International Stem Cell's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Net Margin % distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Net Margin % falls into.


;
;

International Stem Cell Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

International Stem Cell's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.209/9.085
=-2.30 %

International Stem Cell's Net Margin for the quarter that ended in Mar. 2025 is calculated as

Net Margin=Net Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-0.256/2.129
=-12.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


International Stem Cell  (OTCPK:ISCO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


International Stem Cell Net Margin % Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


International Stem Cell Business Description

Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027

International Stem Cell Headlines

From GuruFocus